SCHEMBL5734191

SCHEMBL5734191

Cc1cc(NC(=O)NCCN2CCN(S(=O)(=O)c3cccc(C#N)c3)CC2)c2ccccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.59
HTR2A P28223 2/20 0.58
DRD2 P14416 2/20 0.58
ADRA2A P08913 1/20 0.58
SLC6A2 P23975 1/20 0.58
HTR2C P28335 1/20 0.58
SLC6A4 P31645 1/20 0.58
TMEM97 Q5BJF2 1/20 0.58
SIGMAR1 Q99720 1/20 0.58
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CCR3 P51677 6/20 0.48
GAA P10253 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GBA1 P04062 1/20 0.45
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734976 0.92 UTS2R (0.59) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5733894 0.90 UTS2R (0.66) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5733669 0.89 UTS2R (0.61) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5734533 0.88 LMNA (0.61) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5734458 0.88 UTS2R (0.59) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5733792 0.88 UTS2R (0.62) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5734152 0.88 UTS2R (0.59) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5735683 0.86 UTS2R (0.58) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL6194414 0.86 UTS2R (0.56) UTS2RHTR2ADRD2ADRA2ASLC6A2
SCHEMBL5956412 0.86 UTS2R (0.61) UTS2RHTR2ADRD2ADRA2ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211707-A1 Piperazine-alkyl-ureido derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2006-09-21 US claimed
EP-1631565-A1 PIPERAZINE-ALKYL-UREIDO DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-03-08 EP claimed
WO-2004099179-A1 PIPERAZINE-ALKYL-UREIDO DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2004-11-18 WO claimed
US-20060211707-A1 Piperazine-alkyl-ureido derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211707-A1 Piperazine-alkyl-ureido derivatives ADRA2C, UTS2R, ADRB2 UTS2R 2/4885HTR2A 21/4885DRD2 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.